AC Immune is the clinical-stage Switzerland-based biopharmaceutical firm, listed on the Nasdaq, that aims to become the global leader in accuracy medicine for the neurodegenerative diseases. The firmgoes on to design, discover, and develop the therapeutic along with the diagnostic products that are intended to stop and modify the diseases caused by the misfolding proteins. AC Immune’s 2 proprietary techs. platforms create the antibodies, vaccines, and small molecules designed to address awide spectrum of the neurodegenerative indications, like AD, i.e., Alzheimer’s disease.
The Firm’s pipeline attributes9 therapeutic and 3 diagnostic outcome candidates – with 5 product candidates in clinical trials, currently. The most advanced and latest of these is the Crenezumab. It is currently in the two Phase three clinical studies for the AD, under the global program that is conducted via the collaboration partner – Genentech (the member of a Roche Group). Other collaborations consist of Biogen, Nestlé Institute of the Health Sciences, Janssen Pharmaceuticals, Essex Bio-Technology, and Piramal Imaging.
Therapeutics, Neuro-orphan diseases, Alzheimer’s disease, Parkinson’s disease, Neurodegenerative diseases, Diagnostics, Misfolded proteins, Down syndrome.
Last Quarter Earnings Of The Ac Immune’s
AC Immune (NASDAQ:ACIU) went on to post its quarterly earnings data recently. The firm reported 0.10 dollars earnings for every share for a quarter, topping off the estimate of Thomson Reuters’ consensus that was of 0.17 dollars by 0.07 dollars. The firm had revenue of about 12.83 dollars million for a quarter when compared to a consensus estimate of 10.30 million dollars.
Price Target Set By The Analysts For Aciu
1 equity research analyst has gone on to issue a 1-year price target for the AC Immune’s stock. The forecasts by them range from 11.00 dollars to 11.00 dollars. On average, they expect AC Immune’s price of the share to reach about 11.00 dollars in the comping twelve months. This simply suggests the possible upside of 32.9 percent from the current price of the stock.
Is ac immune receiving any favorable news coverage
The media coverage regardingthe stock of ACIU has been continuously trending somewhat positively, in recent times. As per the InfoTrie,which ranks the sentiment of the media coverage viaanalyzing more than 6,000 news andblog sources. And this, in itself, is a piece of favorable news coming from the InfoTrie. for the NASDAQ: ACIU at https://www.webull.com/quote/nasdaq-aciu.
And that very much sums up the NASDAQ and ACIU. Hopefully, this guide will provide all the information you have been trying to find on the working of the stock of ACIU in the market. You can get more stock information from stock trading simulator. Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.